Optimisation of microfabricated devices for neural circuit modelling DOI

B Sophie

i-manager s Journal on Chemical Sciences, Journal Year: 2024, Volume and Issue: 4(3), P. 22 - 22

Published: Jan. 1, 2024

The increasing prevalence of neurodegenerative diseases such as Parkinson's and Alzheimer's necessitate more advanced neural circuit models for research drug development. Traditional rodent fail to replicate human brain complexity, leading high late-stage clinical trial failure rates. This study presents the development optimisation a humanised microfluidic in vitro neuronal model using compartmentalised microfabricated devices culture SH-SY5Y neurons. differentiation protocol was refined promote long, functional neurons suitable forming unidirectional circuits. Electrophysiological assessment through calcium imaging multi-electrode array (MEA) recordings confirmed activity. successful integration into PDMS demonstrates potential this long-term studies behaviour. Further developments will enhance connectivity disease modelling capabilities.

Language: Английский

Challenges and Future Perspectives in Modeling Neurodegenerative Diseases Using Organ‐on‐a‐Chip Technology DOI Creative Commons
Francesca Michela Pramotton, Sarah Spitz,

Roger D. Kamm

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: 11(32)

Published: June 23, 2024

Abstract Neurodegenerative diseases (NDDs) affect more than 50 million people worldwide, posing a significant global health challenge as well high socioeconomic burden. With aging constituting one of the main risk factors for some NDDs such Alzheimer's disease (AD) and Parkinson's (PD), this societal toll is expected to rise considering predicted increase in population limited progress development effective therapeutics. To address failure rates clinical trials, legislative changes permitting use alternatives traditional pre‐clinical vivo models are implemented. In regard, microphysiological systems (MPS) organ‐on‐a‐chip (OoC) platforms constitute promising tool, due their ability mimic complex human‐specific tissue niches vitro. This review summarizes current modeling using OoC technology discusses five critical aspects still insufficiently addressed date. Taking these into consideration future MPS will advance vitro translational value setting.

Language: Английский

Citations

12
Unveiling the Heart’s Hidden Enemy: Dynamic Insights into Polystyrene Nanoplastic-Induced Cardiotoxicity Based on Cardiac Organoid-on-a-Chip DOI

Tianyi Zhang,

Sheng Yang, Yiling Ge

et al.

ACS Nano, Journal Year: 2024, Volume and Issue: 18(45), P. 31569 - 31585

Published: Nov. 1, 2024

Exposure to micro- and nanoplastics (MNPs) has been implicated in potential cardiotoxicity. However, vitro models based on cardiomyocyte cell lines lack crucial cardiac characteristics, while interspecies differences animal compromise the reliability of conclusions. In addition, current research predominantly focused single-time point exposures MNPs, neglecting comparative analyses injury across early late stages. Moreover, there remains a large gap understanding susceptibility MNPs under pathological conditions. To address these limitations, this study integrated organoids (COs) organ-on-a-chip (OoC) technology develop organoid-on-a-chip (COoC), which was validated for cardiotoxicity evaluation through multiple dimensions. Based COoC, we conducted dynamic observation damage caused by short- long-term exposure polystyrene (PS-NPs). Oxidative stress, inflammation, disruption calcium ion homeostasis, mitochondrial dysfunction were confirmed as mechanisms PS-NP-induced events stages, fibrosis emerged prominent feature Notably, low-dose exacerbated myocardial infarction symptoms states, despite no significant shown healthy models. conclusion, findings further deepened our cardiotoxic effects introduced promising platform assessing

Language: Английский

Citations

4
Gut-Liver-Immune Modular Multi-organ Chip for Non-alcoholic Fatty Liver Disease (NAFLD) Model DOI
Seong Hee Kim, Jaejung Kim, Jong Hwan Sung

et al.

BioChip Journal, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 10, 2025

Language: Английский

Citations

0
Motor Neuron Disorder DOI
Poonam Maurya, Preeti Gupta,

K. A. Shaima

et al.

Advances in medical education, research, and ethics (AMERE) book series, Journal Year: 2025, Volume and Issue: unknown, P. 541 - 584

Published: Jan. 10, 2025

Motor neuron disorder (MND) affects brain and spinal cord motor neurons that drive muscle movement. disease-induced degeneration limits limb movements, breathing, eating, speaking. Riluzole, edaravone, levodopa, baclofen, phenytoin, quinine, amitriptyline, fluvoxamine are FDA-approved MND drugs. They have several side effects barely extend the patient's life by two to three months. These treatments threaten long-term drug use. Thus, treatment must be low-cost, natural, relatively side-effect-free. Ayurveda, Unani, Siddha, Chinese, homoeopathy all researched a variety of plants for their ability treat MND. Ayurvedic, Siddha traditional medical systems among those worldwide authorised use herbal in This chapter discusses aetiology, conventional treatments, neuroprotective phytochemical research, national regulations, nano-formulation breakthroughs treatment.

Language: Английский

Citations

0
Decoding microglial functions in Alzheimer’s disease: insights from human models DOI
Chandrika Rao, Stefan Semrau, Valentina Fossati

et al.

Trends in Immunology, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
Navigating Neurodegeneration: Integrating Biomarkers, Neuroinflammation, and Imaging in Parkinson’s, Alzheimer’s, and Motor Neuron Disorders DOI Creative Commons
Masaru Tanaka, Simone Battaglia, Donato Liloia

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(5), P. 1045 - 1045

Published: April 25, 2025

Neurodegenerative diseases represent a daunting global challenge, affecting millions worldwide and imposing significant clinical socioeconomic burdens [...]

Language: Английский

Citations

0
Comprehensive Review of in vitro Gut-Brain Axis Models in Parkinson’s Disease Research DOI Creative Commons
John Nicholas Cauba,

Jonathan C. G. Woo,

Robert E. Wiggins

et al.

Brain Organoid and Systems Neuroscience Journal, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
Unlocking the Gates: Therapeutic Agents for Noninvasive Drug Delivery Across the Blood-Brain Barrier DOI

Courtney Culkins,

Roman Adomanis,

Nathan Phan

et al.

Molecular Pharmaceutics, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 26, 2024

The blood-brain barrier (BBB) is a highly selective network of various cell types that acts as filter between the blood and brain parenchyma. Because this, BBB remains major obstacle for drug delivery to central nervous system (CNS). In recent years, there has been focus on developing modifiable platforms, such monoclonal antibodies (mAbs), nanobodies (Nbs), peptides, nanoparticles, both therapeutic agents carriers targeted treat cancers diseases. Methods bypassing can be invasive or noninvasive. Invasive techniques, transient disruption using low pulse electrical fields intracerebroventricular infusion, lack specificity have numerous safety concerns. this review, we will noninvasive transport mechanisms offer high levels biocompatibility, personalization, are regarded generally safer than their counterparts. Modifiable platforms designed noninvasively traverse through one more following pathways: passive diffusion physio-pathologically disrupted BBB, adsorptive-mediated transcytosis, receptor-mediated shuttle-mediated somatic gene transfer. Through understanding pathways, new applications, including Chimeric Antigen Receptors T-cell (CAR-T) therapy, approaches across emerging.

Language: Английский

Citations

2
Advances and Challenges of Bioassembly Strategies in Neurovascular In Vitro Modeling: An Overview of Current Technologies with a Focus on Three-Dimensional Bioprinting DOI Open Access

Salvatore Mancuso,

Aditya Bhalerao, Luca Cucullo

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(20), P. 11000 - 11000

Published: Oct. 12, 2024

Bioassembly encompasses various techniques such as bioprinting, microfluidics, organoids, and self-assembly, enabling advances in tissue engineering regenerative medicine. Advancements bioassembly technologies have enabled the precise arrangement integration of cell types to more closely mimic complexity functionality neurovascular unit (NVU) that other biodiverse multicellular structures. In this context, bioprinting offers ability deposit cells a spatially controlled manner, facilitating construction interconnected networks. Scaffold-based assembly strategies provide structural support guidance cues for growth, formation complex bio-constructs. Self-assembly approaches utilize inherent properties drive spontaneous organization interaction neuronal vascular components. However, recreating intricate microarchitecture functional characteristics tissue/organ poses additional challenges. materials hold great promise addressing these The further refinement technologies, improved resolution incorporation multiple types, can enhance accuracy biological constructs; however, developing bioinks growth cells, viability, while maintaining compatibility with process remains an unmet need field, advancements design bioactive biodegradable scaffolds will aid controlling adhesion, differentiation, vascularization within engineered tissue. Additionally, integrating advanced imaging analytical real-time monitoring characterization bioassembly, aiding quality control optimization. While challenges remain, ongoing research technological propel field forward, paving way transformative developments engineering. This work provides overview advancements, challenges, future perspectives fabricating constructs add-on focus on technologies.

Language: Английский

Citations

2
A Human Brain-Chip for Modeling Brain Pathologies and Screening Blood–Brain Barrier Crossing Therapeutic Strategies DOI Creative Commons
Shek Man Chim, Kristen E. Howell, Alexandros G. Kokkosis

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(10), P. 1314 - 1314

Published: Oct. 10, 2024

The limited translatability of preclinical experimental findings to patients remains an obstacle for successful treatment brain diseases. Relevant models elucidate mechanisms behind pathogenesis, including cell-specific contributions and cell-cell interactions, support targeting prediction drug responses in humans are urgently needed, given the species differences blood-brain barrier (BBB) functions. Human microphysiological systems (MPS), such as Organ-Chips, emerging a promising approach address these challenges. Here, we examined advanced Brain-Chip that recapitulates aspects human cortical parenchyma BBB one model.

Language: Английский

Citations

0